These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 19783548)
1. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Jung J; Xu K; Lessing D; Bonini NM Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548 [TBL] [Abstract][Full Text] [Related]
2. CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration. Liman J; Deeg S; Voigt A; Voßfeldt H; Dohm CP; Karch A; Weishaupt J; Schulz JB; Bähr M; Kermer P J Neurochem; 2014 Jun; 129(6):1013-23. PubMed ID: 24548080 [TBL] [Abstract][Full Text] [Related]
3. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324 [TBL] [Abstract][Full Text] [Related]
4. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007 [TBL] [Abstract][Full Text] [Related]
5. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371 [TBL] [Abstract][Full Text] [Related]
6. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Rüb U; de Vos RA; Brunt ER; Sebestény T; Schöls L; Auburger G; Bohl J; Ghebremedhin E; Gierga K; Seidel K; den Dunnen W; Heinsen H; Paulson H; Deller T Brain Pathol; 2006 Jul; 16(3):218-27. PubMed ID: 16911479 [TBL] [Abstract][Full Text] [Related]
7. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD. Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414 [TBL] [Abstract][Full Text] [Related]
9. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis. Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066 [TBL] [Abstract][Full Text] [Related]
10. [Polyglutamine-expanded ataxin-3 is degraded by autophagy]. Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862 [TBL] [Abstract][Full Text] [Related]
11. Protein interacting with C kinase (PICK1) is a suppressor of spinocerebellar ataxia 3-associated neurodegeneration in Drosophila. McGurk L; Bonini NM Hum Mol Genet; 2012 Jan; 21(1):76-84. PubMed ID: 21949352 [TBL] [Abstract][Full Text] [Related]
12. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437 [TBL] [Abstract][Full Text] [Related]
13. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897 [TBL] [Abstract][Full Text] [Related]
14. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362 [TBL] [Abstract][Full Text] [Related]
16. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202 [TBL] [Abstract][Full Text] [Related]
17. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation. Chou AH; Chen YL; Hu SH; Chang YM; Wang HL Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423 [TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. Evert BO; Vogt IR; Vieira-Saecker AM; Ozimek L; de Vos RA; Brunt ER; Klockgether T; Wüllner U J Neuropathol Exp Neurol; 2003 Oct; 62(10):1006-18. PubMed ID: 14575237 [TBL] [Abstract][Full Text] [Related]
19. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100 [TBL] [Abstract][Full Text] [Related]
20. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]